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Summary  
Congenital disorders of glycosylation (CDG) are a heterogeneous and rapidly growing group of diseases caused 
by abnormal glycosylation of proteins and/or lipids. Mutations in genes involved in the homeostasis of the 
endoplasmic reticulum (ER), the Golgi apparatus and the vesicular trafficking from the ER to the ER-Golgi 
intermediate compartment (ERGIC) have been found to be associated with CDG.  
Here, we report the first description of a patient with defects in both N- and O-glycosylation combined with a 
delayed vesicular transport in the Golgi apparatus due to mutations in TRAPPC11, a subunit of the TRAPPIII 
complex. TRAPPIII is implicated in the anterograde transport from the ER to the ERGIC as well as in the 
vesicle export from the Golgi apparatus. This report expands the spectrum of genetic alterations associated with 
CDG, providing new insights for the diagnosis and the understanding of the physiopathological mechanisms 
underlying glycosylation disorders. 
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Congenital disorders of glycosylation (CDG) are a heterogeneous and rapidly growing group of diseases caused 
by abnormal glycosylation of proteins and/or lipids. Human CDG include mutations in genes involved in the 
homeostasis of the endoplasmic reticulum (ER) and the Golgi apparatus (GA) machinery. CDG patients show a 
highly heterogeneous clinical phenotype, usually presenting with symptoms during the neonatal period or 
infancy. The course of the disease is generally severe and the affected individuals show multiorgan involvement 
including central nervous system, muscle, liver, endocrine system, and coagulation abnormalities (Willett et al., 
2013; Freeze et al., 2015). Although the altered glycoconjugates are diverse, the diagnosis of these individuals 
relies on the analysis of the glycosylation pattern of serum proteins. Serum transferrin (Tf) is the N-
glycoprotein most widely used as a tool to detect N-glycosylation defects. In addition, apoCIII analysis, a 
mucin-type O-glycoprotein, is also useful to detect O-glycosylation defects. In fact, the aberrant glycosylation 
patterns of these proteins are reliable biomarkers that point to the potential molecular defects underlying these 
diseases: defects of N-glycan assembly (CDG-I), or N-glycan processing (CDG-II), or combined defects of N- 
and O-glycosylation.  
Mutations in genes involved in the homeostasis of the ER and the GA as well as those implicated in the vesicle 
trafficking from the ER to the ER-Golgi intermediate compartment (ERGIC) have been found to be associated 
with CDGs. Indeed, mutations in genes encoding for proteins implicated in vesicular Golgi transport, such as 
the Conserved Oligomeric Golgi (COG) complex subunits  [COG1 (MIM 606973), COG2 (MIM 606974), 
COG3 (MIM606975), COG4 (MIM606976), COG5 (MIM606821), COG6 (MIM606977), COG7 (MIM 
606978), COG8 (MIM606979)] were first described as a cause of N-glycosylation type II and O-glycosylation 
defects (Rosnoblet  et al., 2013).  In recent years, the implementation of next generation sequencing 
technologies has contributed decisively to the description of new CDGs and allowed the identification of new 
disease-causing mutations in genes encoding for proteins implicated in the homeostasis of the Golgi apparatus 
[ATP6V0A2 (MIM 611716), TMEM165 (MIM 614726) and TMEM199, (MIM 616815)].  
Using whole exome sequencing we have identified the first CDG patient with a defect in N- and O-
glycosylation combined with a delayed ER to Golgi trafficking due to mutations in TRAPPC11 (MIM 615356), 
a subunit of the TRAPP III complex.  
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The patient was a boy from non-consanguineous parents. He was born prematurely at 33 weeks of gestation and 
weighed 1,550g. He presented hypotonia and a malformation syndrome, with microcephaly, retrognatia, 
campydactilia, high foot arches (pes cavus) and abnormal facies. MRI showed brain atrophy. Later on, he 
developed cholestatic liver, recurrent thrombopenia, nephropathy with polyuria, alcalosis, hypernatremia and 
hypercalciuria, and also osteopathy with osteopenia and spontaneous fracture of the tibia. Neurophysiologic 
studies revealed motor and sensitive peripheral neuronopathy and an altered central auditory discrimination. He 
had recurrent infections, with moderate elevation of lactate. He died at 5 months of age.  
Extensive metabolic studies were performed at 4 months of age. Metabolite analysis of plasma and urine 
included amino acids, organic acids, acyl carnitines, free fatty acids, very long chain fatty acids, 
polyunsaturated fatty acids, branched chain fatty acids and sterols. All of them showed normal results. Spleen 
necropsy showed hyperactivities of some lysosomal enzymes (ß-galactosidase, ß-hexosaminidase and ß-
glucuronidase). However, ß-glucurocerebrosidase, galactocerebrosidase, ß-hexosaminidase, arilsulfatase and N-
acetyl-α-galactosaminidase activities were normal in cultured fibroblasts.  
Isoelectric focusing of serum Tf showed a glycosylation pattern compatible with CDG type II (Figure 1A). 
SELDI-TOF-MS analysis of plasma glycans revealed an abnormal percentage of N-glycan structures compared 
to control values, with low biantennary and high monoantennary types of glycans (Supplementary Figure 1). 
These results were in agreement with those found through the analysis of serum Tf. Moreover, the apoCIII 
glycosylation pattern showed a clear increase of the non-sialylated forms (Figure 1A). These observations 
suggested a combined defect of both N- and O-glycosylation, pointing to a defect of the GA function. Therefore, 
alterations in the subunits of the COG complex (COG1-8) were analyzed by western blot and Sanger 
sequencing but no alterations were found in any of the COG subunits (data not shown). Consequently, we 
performed whole-exome sequencing of the patient and his healthy parents (Figure 1B). Since the biochemical 
phenotype showed a defect in both N- and O-glycosylation we filtered for variants of genes encoding for 
proteins involved in vesicles transport as well as in ER and GA functions. We used several filtering strategies 
and when a recessive inheritance pattern was postulated we identified two heterozygous missense mutations in 
TRAPPC11 (transport protein particle complex 11). These mutations (c.1141C>G and c.3311A>G) were 
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predicted to change proline 381 to alanine (p.Pro381Ala) and threonine 1104 to alanine (p.Thr1104Ala), 
respectively (Figure 1B-C). The c.1141C>G mutation was not annotated in the Exome Aggregation Consortium 
(ExAC) database. Interestingly, the c.3311A>G substitution (rs78663235) has already been reported in the 
ExAC database with a global allele frequency of 0.0015, but no homozygous individuals for this change have 
been reported in European population. Compound heterozigosity was corroborated by the carrier status of the 
father (c.[3311A>G]+[=]) and the mother (c.[1141C>G]+[=]). Results were confirmed by Sanger sequencing.  
TRAPPC11 encodes for a large protein of 1133 amino acids with two conserved functional regions: the foie gras 
and gryzum domains (Figure 1C). TRAPPC11 has been described to be involved in the assembly and integrity 
of the TRAPP III complex, which is implicated in the anterograde vesicular membrane transport from the ER to 
the ERGIC as well as in vesicle mediated export from the Golgi in mammals (Kim et al., 2006; Scrivens et al., 
2011; Brunet et al., 2014). The two missense variants identified in our patient correspond to highly conserved 
amino acids in higher eukaryotes, one of them within the foie gras domain (Figure 1C and Supplementary 
Figure 2). The fact that the TRAPPC11 protein levels in fibroblasts of the patient were similar to those seen in 
control cells suggest that these mutations do not compromise the stability of the protein but likely its function in 
the whole complex (Figure 1D). Moreover, the subcellular localization of TRAPPC11 was not affected by the 
mutations reported in this patient, since the protein properly localizes in the GA, as expected (Supplementary 
Figure 3). 
Previous studies identified mutations in TRAPPC11 in three families with a clinical phenotype of muscular 
dystrophy and myopathy with movement disorders and intellectual disability (Bögershausen et al., 2013) and in 
another patient with congenital muscular dystrophy with fatty liver and infantile-onset cataracts (Liang et al., 
2015), but none of these patients were identified to be associated with an abnormal Tf or ApoCIII profile, nor 
with a CDG syndrome. Immunofluorescence studies using antibodies against cis and trans-Golgi markers 
demonstrated a severe fragmentation of the GA in one of the previous reports (Bögershausen et al., 2013). 
Intriguingly, the morphology of the GA was normal in fibroblasts from our patient, as no significant differences 
were found in the degree of Golgi compaction compared to control cells (Figure 1A). As TRAPPC11 is known 
to be involved in ER to Golgi vesicular trafficking, we therefore tested whether this pathway was affected by 
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TRAPPC11 mutations. Thus, cells were treated with brefeldin A (BFA), an inhibitor of the ER-Golgi 
anterograde transport (Jackson et al., 2000). Upon BFA treatment both, patient and control fibroblasts showed 
the complete disassembly of the GA (Figure 1A). Interestingly, after the removal of BFA, a significant delay in 
the reassembly of the GA was observed in patient fibroblasts. These results revealed a defect in the anterograde 
vesicular transport in the TRAPPC11 patient reported here (Figure 1A). In addition, the functionality of the 
retrograde Golgi vesicle transport was also assessed in our patient but no abnormalities were observed (data not 
shown). These results are in agreement with the vesicular stomatitis virus (VSV-G) trafficking defect observed 
in the patients reported by Bögershausen et al (2013).  
Previous studies in mammalian cellular models have demonstrated that the presence of TRAPPC11 is critical to 
keep the integrity of the TRAPP III complex, as its total depletion resulted in strong fragmentation of both, the 
Golgi apparatus and the ERGIC (Scrivens et al., 2011. However, in our patient an alteration in the GA dynamics 
was only detected upon BFA treatment. We hypothesise that the normal expression levels and the correct 
subcellular localization of the mutant TRAPPC11 protein of our patient may be sufficient to maintain, at least 
partially, the integrity of the TRAPP III complex and, subsequently, the structure of the Golgi apparatus 
regardless of the evident ER-Golgi anterograde transport defect (Figure 1D, Supplementary Figure 3A). 
However, the question whether the slight TRAPPC11 alteration resulted in such a severe clinical phenotype 
remains unanswered. 
The main biochemical feature of the TRAPPC11 patient reported here is the abnormal N and O-glycosylation 
pattern detected in plasma Tf and apoCIII proteins (Figure 1A). This finding is novel and provides a reliable 
biochemical marker for the diagnosis of this disorder. Moreover, our observations are supported by a recently 
published study using a zebrafish model carrying a mutation in the TRAPPC11 foie gras domain (DeRossi et al., 
2016). In that work, the authors demonstrated that lipid-linked oligosaccharides were decreased in the 
TRAPPC11 mutant animals and hypothesised that TRAPPC11 deficiency causes a dysfunction in the synthesis 
of dolichol, a substrate required for the protein N-glycosylation, and the induction of the unfolded-protein 
response (UPR). Moreover, HeLa cells treated with siRNA against TRAPPC11 showed an abnormal 
accumulation of the non-glycosylated form of the signal sequence receptor α (SSR1), a protein marker with two 
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glycosylation sites not processed in the GA (DeRossi et al., 2016). Interestingly, the downregulation of other 
TRAPP III subunits showed no defects in protein glycosylation. In fact, it is known that several TRAPP III 
complex subunits have additional functions other than vesicle trafficking (Gedeon  et al., 1999; Milev et al., 
2015). Thus, in addition to the role in maintaining TRAPP III complex integrity, TRAPPC11 may also be 
involved in the regulation of N-linked glycosylation and, as a consequence, protein glycosylation might be 
altered in patients with TRAPPC11 mutations.  
The patient reported here showed,a constitutive activation of the UPR, mimicking the observations made in 
TRAPPC11-deficient cellular and animal models (Figure 2) (DeRossi et al., 2016). Moreover, our results 
suggested that the N-glycosylation defects observed in our patient cannot only be attributed to a dysfunction in 
the dolichol synthesis pathway, as previously hypothesised (DeRossi et al., 2016), since dolichol levels in liver 
necropsy from our patient were similar to those found in age matched controls (Supplementary Figure 4). 
Therefore, the strong UPR activation observed in our patient suggests that the glycosylation defects may result 
in the accumulation of unfolded/misfolded proteins in the ER regardless of the dolichol levels. Altogether these 
observations point to a widespread role of TRAPPC11 in the molecular and cellular pathways involved in 
protein glycosylation and Golgi vesicular transport. 
In summary, this report expands the spectrum of genetic alterations associated with CDG, providing new 
insights into the diagnosis as well as for the understanding of the physiopathological mechanisms underlying 
vesicle trafficking defects and glycosylation disorders. We highlight the importance of an accurate biochemical 
characterization to direct the genetic data analysis when using next generation sequencing tools. Our study 
demonstrates that TRAPPC11 deficiency could lead to a disorder targeting the GA function which might be 
readily identified by routine screening for abnormal glycosylation patterns of plasma proteins.  
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FIGURE LEGENDS 
Figure 1. Identification of TRAPPC11 mutations in a patient with defects in N- and O-glycosylation. (A) 
Transferrin and Apo CIII glycosylation patterns of a control individual (C), a CDG type I patient (CDG-I) and 
the TRAPPC11 patient (P). (B) Exome data analysis and filtering steps leading to the identification of 
TRAPPC11 as a putative genetic cause of the disease. (C) Human TRAPPC11 protein scheme showing the 
position of the identified mutations. (D) Western blot analysis of TRAPPC11 in patient fibroblasts (P) and in a 
control individual (C). SDHA was used as loading control.  
Figure 2. ER-to-Golgi anterograde membrane flow is defective in the TRAPPC11 patient.  (A) Fibroblasts 
from the TRAPPC11 patient and from a control individual were treated with brefaldin A (BFA) for 15 min to 
block ER-Golgi anterograde transport. (B) After BFA removal, the percentage of cells with assembled Golgi 
apparatus together with the (C) Golgi compactation index (calculated as 4π*Σ(areas)/Σ(perimeter)
2
) were 
analyzed at different time points, using the Fiji image processing package (Schindelin  et al., 2012). Antibody 
against GM130 was used to stain the Golgi apparatus. (D) Fibroblasts from TRAPPC11 patient and from a 
control individual were analyzed by qPCR for expression of four UPR (unfolded protein response) effectors and 
target genes using the comparative Ct method. GAPDH gene was used as an internal control. Results are 
expressed in relative units (RU),* p<0.05. 
Supplementary Figure 1. Analysis of glycans in negative ion mode by SELDI-TOF-MS in plasma from the 
TRAPPC11 patient showed an altered percentage of N-glycan structures compared to control values. The major 
abnormal species corresponds to biantennary N-linked glycan that lacks a single SA residue and a single Gal 
residue. Relative amounts are presented as a percentage of the total identified N-linked glycans structures 
compared to control values. n.d.: not detectable; SA: sialic acid; Gal: galactose; GlcNac: N-Acetylglucosamine. 
Supplementary Figure 2. Conservation of the aminoacids mutated in the TRAPPC11 patient among different 
species. The mutated aminoacids are indicated by an arrow.   
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Supplementary Figure 3. Subcelullar localization of the TRAPC11 protein in fibroblasts from the TRAPPC11 
patient and in a control individual. Antibodies were anti-TRAPPC11, anti-GM130 (Golgi) and anti-PDI (ER). 
 
Supplementary Figure 4. Analysis of dolichol in liver necropsy from the TRAPPC11 patient and control 
individuals by HPLC according to Marino et al (1998). Values of dolichol are expressed in ng/mg frozen liver.  
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